Profile of interleukin-22 in gut mucosal health and disease

Russell B Foxall1
Susana M Fernandes1,2
Ana E Sousa1

1Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; 2Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal

Correspondence: Russell B Foxall
Ana E Sousa’s Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal
Tel +351 21 799 9525
Fax +351 21 799 9525
Email rfoxall@medicina.ulisboa.pt

Abstract: Interleukin-22 (IL-22) is produced by both innate and adaptive immune cells and specifically targets nonhematopoietic cells; this provides a unique mechanism linking host immunity to mucosal homeostasis and led to its establishment as a key player in the maintenance of barrier integrity at mucosal sites particularly in the gut. Our aim is to provide an overview of the role of this cytokine in maintaining gut mucosal homeostasis in the steady state and in disease. IL-22 has two main functions in healthy states: to help shape the gut microbial flora via the induction of mucins and antimicrobial peptides and to maintain barrier integrity through the induction of epithelial cell proliferation and/or survival. Given the risk of malignancy related to uncontrolled cell growth per se, it is not surprising that the expression of this cytokine is tightly regulated by a complex interactive signaling network. This consists of a combination of cytokines and various environmental signals that can be derived directly from the diet and/or the gut microbiota. A role for IL-22 in response to gut infection has been reported. Here, we will focus specifically on how reduced levels of this cytokine can exacerbate disease pathology, as in the case of human immunodeficiency virus infection. We will also review its association with inflammatory bowel disease, where its net contribution likely reflects the balance between its pro- and anti-inflammatory functions, as well as its role in malignancy, specifically colorectal cancer. Finally, we will briefly discuss the potential pros and cons of targeting IL-22 in these, and other, clinical situations.

Keywords: IL-22, gut, inflammation, infection, cancer

Introduction and aim

Since its discovery 15 years ago, interleukin-22 (IL-22) has emerged as a key player in the maintenance of mucosal homeostasis and preservation of barrier sites.1 Conversely, it has been linked to a number of pathologies, including autoimmune disorders2 and cancer.3

The aim of this review is to outline how IL-22 helps maintain mucosal homeostasis in steady-state conditions and during pathological insults, and, in turn, how this may, in the context of its dysregulated expression, result in pathology. As the role of IL-22 in a range of organs and tissues has recently been reviewed in depth,4 we will focus here on its multifaceted role in human gut mucosa, in health and during infection, and the ways in which it may contribute to important gut pathologies such as inflammatory bowel disease (IBD) and colorectal cancer (CRC).

IL-22: a brief introduction

IL-22 was first described by Dumoutier et al5 as “IL-10-related T-cell-derived inducible factor (IL-TIF).” Originally considered an IL-10 cytokine family member,5 it has
recently been reassigned to the IL-20 cytokine subfamily, with whose other members it shares considerable structural homology. The IL-22 gene is located on chromosome 12q15 in humans and chromosome 10 in mice. Human IL-22 is expressed as a 179-amino-acid protein, sharing reasonably high homology with its murine counterpart (79%) as well as 25% homology with IL-10. The active, monomeric form of IL-22 is secreted as a 146-amino-acid protein consisting of six helices, four of which form a bundle characteristic of Class II cytokines, and a small N-terminal helix.

Where is IL-22 produced?
Constitutive expression of IL-22 was initially observed in the thymus and brain, with induced expression subsequently being observed in many other tissues such as the gut, liver, skin, lung, pancreas, and spleen. For the purposes of this review, we will concentrate on IL-22 in the context of the gut mucosa.

Which cells produce IL-22?
Apart from a couple of reports of nonlymphoid cells producing IL-22 under specific conditions, the available human and murine data indicate that cells of lymphoid origin represent the primary source of this cytokine, with both innate and adaptive immune cells able to produce IL-22 (Table 1).

<table>
<thead>
<tr>
<th>Lymphoid cells</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4+ αβ T-cells (Th1, Th17, Th22)</td>
<td>5,14,15</td>
</tr>
<tr>
<td>CD8+ αβ T-cells (Tc22)</td>
<td>16</td>
</tr>
<tr>
<td>γδ T-cells</td>
<td>17</td>
</tr>
<tr>
<td>NK cells</td>
<td>18</td>
</tr>
<tr>
<td>NK cells</td>
<td>19,20</td>
</tr>
<tr>
<td>ILC3s</td>
<td>14,21,22</td>
</tr>
<tr>
<td>Mast cells</td>
<td>23</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>24</td>
</tr>
</tbody>
</table>

Abbreviations: Th, T-helper; Tc, T-cytotoxic; NK-T, natural killer T-cell; ILC3s, Class 3 innate lymphoid cells; IL-22, interleukin-22.

The IL-22 receptor
The heterodimeric receptor of IL-22 (IL-22R) belongs to the Type 2 cytokine receptor family and consists of the IL-22R1 chain and the β-chain of the IL-10 receptor (IL-10Rβ, Figure 1). The former’s intracellular domain is associated with Tyk2 and the latter’s with Jak1 (Figure 1).

Expression pattern
IL-22R is almost exclusively expressed on nonhematopoietic cell populations in various tissues, including the gut mucosa, skin, pancreas, lung, and liver.

Downstream effects of IL-22/IL-22R signaling
Binding of IL-22 to its receptor leads to phosphorylation of the associated kinases, and consequently members of the STAT family, primarily STAT3, as well as activation of the MAP kinase and p38 pathways (Figure 1). In general, signaling via IL-22R is associated with promotion of cell survival and/or proliferation both of which likely contribute to its pivotal role in tissue regeneration, a process observed in various models of tissue damage. It also mediates certain tissue-specific activities such as induction of antimicrobial peptides in the gut and skin. Data also suggest that, under certain circumstances, IL-22 can act as a proinflammatory cytokine. The unique combination of the cell subsets that account for the majority of IL-22 production (immune cells) and those which express its receptor (nonhematopoietic cells) endows this cytokine with its distinctive ability to link these two compartments and act as a key player in maintaining homeostasis at mucosal and/or barrier sites.
Role of IL-22 in host defense

Various studies, in both mice and humans, indicate that IL-22 can play a role in immunity to infection caused by various classes of pathogens, including bacteria, viruses, and parasites (Table 2). It is important to note that in many cases, the data regarding the impact of IL-22 in these contexts are contradictory, with reports suggesting that it can help limit and/or exacerbate pathology. The overall outcome in any given pathological context likely reflects the balance struck between the ability of IL-22 to mediate tissue repair and its proinflammatory capacity. The local cytokine environment in which IL-22 is being produced may also influence whether its effects are ultimately beneficial or deleterious.

Of note, IL-22 has been shown to induce the production of acute-phase proteins by hepatocytes. More recently, a systemic role of IL-22 in the context of infection has been reported, with IL-22 being shown to induce C3 production and augment C3-mediated phagocytosis in a murine model of disseminated Clostridium difficile. Thus, it is possible that this cytokine may help mediate protection against infection beyond its normal tissue-specific functions.

IL-22 and the gut

Production of IL-22 has been observed throughout the gastrointestinal (GI) tract. Here, we will focus on its role in the context of the gut mucosa, particularly that of the colon, as this represents an ideal model to illustrate the dual nature of this cytokine.

The gut mucosa

The gut mucosa represents the largest body surface in contact with the external environment, functioning as a selective portal that allows the passage of nutrients while keeping foreign organisms at bay. An active interplay occurs between the gut microbiota and the cellular components of the gut (epithelial, stromal, and immune cells). This interaction shapes both ecosystems in a continuous process starting after birth, which ultimately helps determine the overall health of the host.

IL-22 and gut homeostasis

IL-22 plays an important role in gut homeostasis. A key contribution is through the maintenance of barrier integrity, with ILC3-produced IL-22 being of particular importance. IL-22 serves several functions in the gut (Figure 2). It regulates epithelial cell proliferation and survival and plays an important role in wound healing. It induces the production of a wide range of proteins required for normal gut epithelial function, including antimicrobial peptides and members of the REG, defensin, and S100 protein families. Furthermore, recent data suggest that IL-22 may play a role in the maintenance and/or repair of epithelial tight junctions.

Regulation of IL-22 production in the gut

There are several lymphocyte subsets of particular relevance in terms of IL-22 production in the gut: αβ CD4+ T-cells (in particular the Th17 and Th22 subsets) and γδ T-cells that patrol the lamina propria and the gut resident ILC3s. Given the ability of IL-22 to promote tissue proliferation and/or survival, coupled with its potential to act as a proinflammatory cytokine, it is not surprising that IL-22

Table 2  IL-22 involvement in the response to pathogens

<table>
<thead>
<tr>
<th>Pathogen targeted</th>
<th>Site of action in infected host</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gram-negative species</td>
<td>Lung</td>
<td>37</td>
</tr>
<tr>
<td>Citrobacter rodentium</td>
<td>Lung</td>
<td>38</td>
</tr>
<tr>
<td>Mycobacterium tuberculosis</td>
<td>Lung</td>
<td>39,40</td>
</tr>
<tr>
<td>Viruses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>Liver</td>
<td>42</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>Liver</td>
<td>41</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>Gut</td>
<td>43,44</td>
</tr>
<tr>
<td>Parasites</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td>Liver</td>
<td>45</td>
</tr>
<tr>
<td>Leishmaniasis</td>
<td>Skin</td>
<td>46</td>
</tr>
</tbody>
</table>

Abbreviation: IL-22, interleukin-22.
production by these cells is tightly regulated via a complex interactive process involving cytokines, environmental factors, and soluble receptors (Figure 3).

**Cytokines**

Cytokines can either positively or negatively regulate IL-22 production. Several cytokines produced by a variety of cell types have been shown to drive production of IL-22, either by directly inducing its expression or by promoting the differentiation and/or survival of IL-22-producing populations. Of these, IL-23, a member of the IL-12 cytokine family, plays a key role, being able to induce expression of this cytokine in a number of immune cells.\(^4\) Dendritic cells (DCs) are a major source of IL-23, particularly in the gut, with murine CD103\(^+\) and CX3CR1\(^+\) DC subsets producing it in response to pathogens and environmental cues. In humans, monocyte-derived dendritic cells have been shown to produce IL-23 on exposure to commensal Gram-negative bacteria.\(^5\) Furthermore, IL-23 production by monocyte-derived dendritic cells was augmented by CD40L/CD40-mediated DC-T-cell interactions.\(^5\) Proinflammatory cytokines, such as IL-\(\beta\) and IL-6, can also induce IL-22 production. The former is particularly relevant in the gut, where it can directly induce IL-22 production by ILCs,\(^6\) and indirectly through its capacity to promote the survival and proliferation of IL-22-producing ILCs.\(^6\) IL-6 can also induce IL-22 production by a variety of cell types, including \(\gamma\delta\) T-cells\(^7\) and ILC3s.\(^6\) IL-21 drives the differentiation of human naive CD8\(^+\) T-cells into Tc22 cells.\(^16\) However, regarding ILC3s, it seems to function by regulating the interaction between the aryl-hydrocarbon receptor (AhR) and the IL-22 promoter, and thus may help integrate IL-22 inductive signals from cytokines and environmental factors. Recent data also suggest a reciprocal relationship between IL-18 and IL-22, with the former able to regulate IL-22 expression in the ileum and the latter inducing IL-18 during *Toxoplasma gondii* infection.\(^67\)

Conversely, several cytokines have been implicated in the suppression of IL-22 production, although the underlying mechanisms differ. Thus, IL-25 may indirectly target IL-22 production by suppressing the production of IL-23.\(^5\) On the other hand, Transforming growth factor (TGF)-\(\beta\) appears to function more directly: although linked with Th17 differentiation,\(^69\) it can suppress IL-22 production\(^70\) in a c-maf-dependent manner.\(^71\) IL-27, a member of the IL-12 cytokine family that is known to have anti-inflammatory properties,\(^72\) also directly blocks IL-22 production by human T-cells, in an suppressor of cytokine signaling 1 (SOCS1)-dependent manner.\(^73\)

**Environmental factors**

Pathogen-associated molecular patterns, a broad class of molecules including both structural components, such as bacterial

---

**Figure 3** IL-22 production and regulation in the gut mucosa.

**Notes:** IL-22 is produced by both innate (ILC3s and \(\gamma\delta\) T-cells) and adaptive (\(\alpha\beta\) CD4\(^+\) Th17 and/or Th22 as well as CD8\(^+\) Tc17 and/or Tc22 subsets) immune cells in the gut. This occurs in response to a variety of signals, including cytokines; most importantly, IL-23 produced by DCs in response to environmental factors, including AhR ligands, dietary-derived compounds, and bacterially derived products featuring PAMPs recognized by PRR. In addition, environmental factors can also regulate IL-22 production by directly targeting IL-23-producing cell populations. Cytokines can also suppress IL-22 production directly, by antagonizing its production (TGF-\(\beta\) and IL-27), or indirectly, by suppressing IL-23 production (IL-25). IL-22-binding protein (IL-22BP), a soluble IL-22 receptor, binds IL-22 and prevents it from signaling its target cell populations.

**Abbreviations:** AhR, aryl-hydrocarbon receptor; DC, dendritic cell; IL, interleukin; PAMP, pathogen-associated molecular pattern; PRR, pattern recognition receptor; TGF-\(\beta\), Transforming growth factor beta; IL-22, interleukin-22.
lipopolysaccharide, and nucleic acids, are recognized by several classes of invariant pattern recognition receptors, such as the Toll-like receptor family. They have been shown to trigger IL-22 production both indirectly by inducing IL-23 production by DCs and directly via TLR2 expressed on IL-22-producing immune cells such as ILC3s and γδ T-cells. In the gut, pattern recognition receptors are expressed on the basal surface of the epithelial cells, ensuring these cells only respond to pathogen-associated molecular patterns when the epithelial barrier is disrupted. The capacity of gut DCs to sample the gut lumen and the two-way conversation between the microbiota and ILC3s also help regulate IL-22 production, further ensuring it is restricted to situations where epithelial damage and/or shifts in microbiota populations (dysbiosis) has occurred.

Various food-derived compounds can regulate IL-22 production. Vitamin D can modulate DC cytokine production and indirectly promote the differentiation of IL-22-producing cells. Gut microbiota also plays an important role in this respect, either indirectly through the release of metabolites or directly via inducing retinoic acid production (a metabolite of vitamin A) by DCs, which can, in turn, induce IL-22 production by ILC3s and γδ T-cells. Conversely, retinoic acid can negatively regulate IL-22 production via the induction of IL-22-binding protein (IL-22BP) by DCs and IL-25 production by enterocyte.

AhR
AhR is a key regulator of IL-22 production in the gut. It is a cytoplasmic receptor with several immune-regulatory functions. Although initially shown to bind environmental toxins such as Dioxin, a range of endogenously derived ligands have subsequently been identified, originating from both dietary sources and the microbiota. Not only is AhR able to drive IL-22 production by ILC3s, it also regulates their development. This is particularly important given the key role ILC3s play in controlling intestinal immunity and inflammation. AhR has also been linked to IL-22 production by several other cell types, such as Vγ2 subset of γδ T-cells, Th22 cells, and neutrophils. It is important to note that the AhR is also expressed in DCs and macrophages, and thus, its activation in these cells may be able to indirectly regulate IL-22 induction.

IL-22BP
This is a soluble form of the IL22R1 receptor chain, encoded by a separate gene, rather than generated by alternative splicing. IL-22BP expression has been observed in various tissues, including the gut. DCs are the major, but not the sole producer, of this soluble receptor.

The binding footprint of IL-22BP on IL-22 overlaps that of the IL22R1, allowing it to directly interfere with the binding of IL-22 to its membrane-bound receptor. The inhibitory effect of IL-22BP is enhanced by the fact that the affinity of its interaction with IL-22 is ~1,000-fold higher than that of IL-22 and the membrane bound form of IL-22R1. As discussed later, IL-22BP interaction with IL-22 may play a role in both IBD and colon cancer.

Overall, it is clear that this complex network, involving a fine balance between the microbiota, immune system, and the epithelial barrier, is vital in maintaining homeostasis in the context of the gut, with disruption of this system potentially leading to inflammation and associated pathologies.

IL-22 and gut immunity
The role of IL-22 in mediating antibacterial immunity in the context of the gut has been widely reported. In particular, it is vital in orchestrating the immune response to Citrobacter rodentium in mice, an experimental model of pathogenic Escherichia coli infection. IL-22 in this context seems to be initially derived from ILC3s, although its production by adaptive immune cells appears necessary in the later stages of infection to allow for effective resolution of the disease.

Of note, IL-22 also helps regulate immune responses to commensal microbiota, such as those targeting segmented filamentous bacteria, with recent data indicating an important role of IL-23 in regulating this process. IL-22 also plays a role in the host response to viral infections in the context of the gut.

It was recently identified as a key player in the response to rotavirus infection in both mice and humans.

Human immunodeficiency virus-1 infection and the gut: the role of IL-22
A good example highlighting the importance of IL-22 in maintaining gut homeostasis in humans is provided by human immunodeficiency virus-1 (HIV-1) infection. HIV-1 infection is characterized by rapid and profound depletion of CD4 T-cells from the GI mucosa, structural deterioration of the gut epithelium, and translocation of microbial products from the gut lumen into the systemic circulation. The combination of these factors is thought to contribute to chronic hyperimmune activation, which we and others have shown to be a hallmark of HIV infection and a major determinant of disease progression. It is also important to note that the interaction between HIV and mucosal barriers...
has important consequences not only for disease pathogenesis but also for transmission.106

HIV-1 infection appears to impact on important IL-22-producing cell populations. A loss of IL-22-producing T-cells in the peripheral blood of antiretroviral therapy (ART)-naive HIV-1+ individuals has been reported.107,108 Circulating ILC3s have also been shown to be depleted in HIV-1+ individuals.109 In simian immunodeficiency virus-infected macaques, a widely used model of HIV-1 infection, depletion of ILC3s was observed in mucosal and systemic lymphoid tissues.110 Furthermore, loss of IL-22-producing cells was associated with mucosal damage in this model.111 The limited human data available suggest that mucosal IL-22 production is reduced in chronic HIV-1 infection.57,112

No consensus has yet been reached as to whether successful ART can result in the restoration of normal gut function.113 Data suggest that disturbances in gut homeostasis persist in the context of ART.57,114,115 We have not only shown that Th22 are depleted in colon biopsies from long-term treated individuals but also observed that the frequency of ILC3s was similar in ART-treated HIV-1 and seronegative individuals.116 This observation, coupled with an apparent lack of gut disturbances in ART-treated individuals, led us to conclude that ART allowed for ILC3 recovery, which, in turn, was sufficient to restore gut homeostasis.116

Nevertheless, long-term ART-treated HIV-1+ individuals still show persistent immune activation that is related to a variety of comorbidities,117 with continued alterations at the level of the gut, such as persistence of microbial dysbiosis.118 Recent data suggest that initiation of ART during the early phase of HIV-1 infection may be more efficient in restoring/preserving normal gut function.112

HIV-1 has also been shown to directly disrupt epithelial tight junctions in an infection-independent manner.119 Kim et al157 demonstrated that IL-22 was able to abrogate this effect, further emphasizing the importance of IL-22’s capacity to interact with epithelia in helping maintain gut homeostasis in the context of HIV infection.

Overall, HIV-1 appears to directly impact on key IL-22-producing lymphocyte populations, with evidence suggesting that ART may allow for the recovery of some of them, at least in the context of long-term treatment, and thus enable some degree of recovery of gut homeostasis.

**IL-22 and IBD**

IBD encompasses a range of chronic relapsing disorders of the GI tract that are primarily characterized by excessive inflammation. Among them, Crohn’s disease (CD) and ulcerative colitis (UC) are of particular clinical relevance in the developed world.120 In general, IBD can be viewed as a disruption of the complex interactions between the gut immune system and its resident microbial flora. Under normal conditions, this allows for tolerance to food-derived antigens as well as to those of commensal bacteria beneficial to the host, while still permitting the generation of immune responses to invading pathogenic species and/or pathobionts. The loss of this fine balance can result in inflammation that, rather than resolving, persists, eventually resulting in a state of chronic intestinal inflammation that typifies IBD.

As recently reviewed by Geremia et al,121 IBD can involve both the innate and adaptive arms of host immunity. Furthermore, cytokines, including IL-22, play a critical role in its pathogenesis.122

However, the role of IL-22 in IBD is complex. Evidence supports a role of IL-22 in driving IBD, through its ability to function as a proinflammatory cytokine.123-125 Certainly, IL-23, a potent inducer of IL-22 production,4 has a key role,126 with an expansion of IL-23-responsive ILCs observed in the context of IBD.127 It is also important to note that Th17 cells can produce both IL-22 and IL-17, with the latter also being associated with the IBD pathogenesis.126 Moreover, a recent study demonstrated that IFN-γ/IL-17-coproducing CD4+ T-cells specifically enriched in the inflamed mucosal tissue of patients with IBD also showed high expression levels of IL-22.128

However, data from mouse models support an important protective role of IL-22 in IBD.129 In humans, a loss of the Th22 subset has been reported in the colon of patients with UC,130 whereas IL-22 production by ILCs has been seen to be impaired in inflamed tissue of patients with CD;131 increased production of IL-22BP, a negative regulator of IL-22 function, has also been observed in human IBD.132 A protective role of IL-22 in human IBD; in this case, UC is further supported by the report of amelioration of symptoms in an individual who deliberately infected themselves with *Trichuris trichiura*, resulting in an expansion of IL-22-producing CD4+ T-cells.131

Thus, it seems that IL-22 can also be beneficial in the context of IBD, which is perhaps not surprising given its capacity to directly interact with gut epithelia and mediate tissue repair in this context.13 However, the suggestion that IL-22 represents a potential therapeutic candidate for IBD129 has to be balanced against the evidence supporting a role of this cytokine in IBD pathogenesis.
IL-22 and cancer

Just as for IBD, IL-22’s role in cancer is complex. Recent data from human studies have linked IL-22 to cancers as diverse as multiple myeloma and glioblastoma. Here, we will focus on IL-22’s role in CRC. The fact that chronic intestinal inflammation is a widely accepted risk factor for CRC development and that, as discussed earlier, IL-22 is upregulated in the context of IBD provides strong circumstantial evidence of a role of this cytokine in CRC. Furthermore, genetic polymorphisms in the IL-22 gene have been identified as a colon cancer risk factor. A complex network of cytokines, including IL-22, underlies CRC. Murine studies provide evidence for a role of IL-22 in CRC. Data from IL-22BP–/– mice indicating increased intestinal tumorigenesis also support a role of augmented IL-22 levels in driving tumor development at this site. In humans, Jiang et al reported an accumulation of tumor-infiltrating lymphocytes that are able to produce IL-22, with IL-22-mediated STAT3 induction promoting tumor growth and metastasis in an in vivo system. Similarly, Th22 cells were found to accumulate in CRC tissue, with subsequent in vitro and in vivo studies again implicating the IL-22/STAT3 signaling axis in cancer cell proliferation and survival. A recent report suggested that IL-22 enhances stemness in the context of CRC by upregulating core stem cell genes such as Nanog. This, in turn, enhanced tumorigenicity, with an association between increased expression levels of these genes and poor patient prognosis also observed. This may be a particularly important role of IL-22 in CRC, given this cytokine’s role in maintaining intestinal stem cell viability in mice.

Increased serum IL-22 has been associated with resistance to chemotherapy in patients with CRC, with an ability to enhance in vitro chemoresistance in CRC cell lines also being reported. This subject has been recently reviewed in depth.

According to the author’s proposed model, IL-22 could exert anticancer effects through its ability to promote pathogen clearance, mediate short-term inflammation, and help both resolve this and promote tissue repair. However, its continued expression could drive tissue dysplasia and, subsequently, tumor formation. Several of its functions could then augment tumor growth, by aiding angiogenesis, tissue invasion, and ultimately metastasis.

Conclusion

IL-22 production and signaling require strict regulation in the gut mucosa to guarantee an adequate balance of its beneficial and potentially deleterious properties, and hence maintain mucosal homeostasis and repair.

In steady-state conditions, it is required to help maintain epithelial cells, which provide the barrier between the host and the external environment. The interactions between a range of lymphoid cells, the microbiota, and other environmental signals ensure the fine tuning of IL-22 levels, such that they maintain barrier function without provoking overt inflammation (Figure 3). It is also interesting to note that the persistent disruption of gut homeostasis observed in HIV infection is linked to a loss of IL-22-producing subsets, further highlighting the importance of this cytokine in maintaining a healthy gut environment.

However, it is easy to imagine that IL-22 could have deleterious effects in the gut, particularly given its ability to enhance epithelial cell survival and/or proliferation. Thus, circumstances where IL-22 production is dysregulated and/or prolonged could lead to epithelial hyperplasia and ultimately cancer.

As IL-22 has been linked to a variety of pathologies outside of the gut, particularly inflammatory skin disorders such as psoriasis and atopic dermatitis, and it has been suggested that it could represent a viable therapeutic target. However, whether its expression would require augmenting or reducing will likely be dictated by the particular clinical situation.

Thus, blocking IL-22 may be of benefit in cancer or autoimmunity, whereas enhancing its expression in the context of certain gut infections or IBD may be beneficial; the latter is supported by data indicating that local delivery of the IL-22 gene to inflamed colonic tissue results in the amelioration of inflammation in a Th2-mediated mouse colitis model.

However, it would be vital to ensure that modulation of IL-22 be restricted to the target tissue to avoid damaging “off-target” side effects.

Disclosure

The authors report no conflicts of interest in this work.

References


45. Foxall et al. International Journal of Interferon, Cytokine and Mediator Research 2016:8

For personal use only.


